KK8123

Phase 2Small molecule

Kyowa Kirin Co., Ltd.

KK8123 is one of 3 small molecule programs targeting X-linked hypophosphatemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

X-Linked HypophosphatemiaRecruiting

X-Linked HypophosphatemiaPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in X-Linked Hypophosphatemia

#DrugCompanyPhaseTrials

Rocaltrol

Jazz Pharmaceuticals

Approved

2 2

KK8123

Kyowa Kirin Co., Ltd.

Phase 2

1 3

Salmon Calcitonin

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

X-Linked Hypophosphatemia

NCT06525636

Clinical

Trials by Indication[1]

X-linked hypophosphatemia1 trial

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

Recruiting· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 1/2·NCT06525636·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KK8123. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KK8123 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KK8123. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyowa Kirin Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Kyowa Kirin Co., Ltd.

KK8123

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

X-linked hypophosphatemia1 trial

References

Drug Info

Quick Facts

Related News